The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate COVID-19 because there is currently insufficient evidence that they improve important outcomes for patients, and both drugs carry potential harms, says a WHO Guideline Development Group (GDG) panel of international experts in The BMJ today.
WHO advises against use of two drugs for non-severe COVID-19
The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate COVID-19 because there is currently insufficient evidence that they improve important outcomes for patients, and both drugs carry potential harms, says a WHO Guideline Development Group (GDG) panel of international experts in The BMJ today.